Performance characteristics of six IMMULITE 2000 TORCH assays

American Journal of Clinical Pathology

Volumn 126, Issue 6, 2006, Pages 900-905

  Owen, William E ^a   Martins, Thomas B ^a   Litwin, Christine M ^b   Roberts, William L ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; Automated; Chemiluminescent immunoassay; Imprecision; Prenatal; TORCH

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; HERPES SIMPLEX VIRUS ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTOZOON ANTIBODY; RUBELLA ANTIBODY; TOXOPLASMA GONDII ANTIBODY; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIAGNOSTIC ACCURACY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MOTHER FETUS RELATIONSHIP; PERINATAL INFECTION; PRENATAL SCREENING; PRIORITY JOURNAL; QUANTITATIVE ASSAY; QUANTITATIVE DIAGNOSIS; RUBELLA VIRUS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SYPHILIS; TOXOPLASMA GONDII;

EID: 33845444027     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/KUA926D3YAPFYQG8     Document Type: Article

References (25)

1. Stegmann BJ, Carey JC. TORCH infections: toxoplasmosis, other (syphilis, varicella-zoster, parvovirus B19), rubella, cytomegalovirus (CMV), and herpes infections. Curr Womens Health Rep. 2002;2:253-258.
2. Gerber S, Hohlfeld P. Screening for infectious diseases. Childs Nerv Syst. 2003;19:429-432.
3. Newton ER. Diagnosis of perinatal TORCH infections. Clin Obstet Gynecol. 1999;42:59-70, 174-175.
4. Oi S, Honda Y, Hidaka M, et al. Intrauterine high-resolution magnetic resonance imaging in fetal hydrocephalus and prenatal estimation of postnatal outcomes with "perspective classification." J Neurosurg. 1998;88:685-694.
5. Skendzel LP, Kiefer DJ, Nakamura RM, et al. Detection and Quantification of Rubella IgG Antibody: Evaluation and Performance Criteria for Multiple Component Test Products, Specimen Handling, and Use of Test Products in the Clinical Laboratory. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997;17(17). Approved Guideline, Document I/LA6-A.
6. Diagnostic Products. IMMULITE 2000 Toxoplasma Quantitative IgG (PIL2KTXQ-14, 2004-12-15). Los Angeles, CA: Diagnostic Products; 2004.
7. Diagnostic Products. IMMULITE 2000 Rubella Quantitative IgG (PIL2KRBQ-9, 2004-11-30) [package insert]. Los Angeles, CA: Diagnostic Products; 2004.
8. Diagnostic Products. IMMULITE 2000 Toxoplasma IgM (PIL2KTM-18, 2004-12-15) [package insert]. Los Angeles, CA: Diagnostic Products; 2004.
9. Diagnostic Products. IMMULITE 2000 Rubella IgM (PIL2KRM-17, 2004-08-31) [package insert]. Los Angeles, CA: Diagnostic Products; 2004.
10. Diagnostic Products. IMMULITE 2000 CMV IgG (PIL2KCV-9, 2004-11-08) [package insert]. Los Angeles, CA: Diagnostic Products; 2004.
11. Diagnostic Products. IMMULITE 2000 Herpes I & II IgG (PIL2KHVG-11, 2005-03-07) [package insert]. Los Angeles, CA: Diagnostic Products; 2005.
12. Mezzasoma L, Bacarese-Hamilton T, Di Cristina M, et al. Antigen microarrays for serodiagnosis of infectious diseases. Clin Chem. 2002;48:121-130.
13. Wilson M, Remington JS, Clavet C, et al, for the FDA Toxoplasmosis Ad Hoc Working Group. Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. J Clin Microbiol. 1997;35:3112-3115.
14. Decoster A, Lecolier B. Bicentric evaluation of Access Toxo immunoglobulin M (IgM) and IgG assays and IMx toxo IgM and IgG assays and comparison with Plarelia Toxo IgM and IgG assays. J Clin Microbiol. 1996;34:1606-1609.
15. Gretch DR, Warren JJ, Bacina RM, et al. Performance characteristics of a commercial antibody-capture enzyme immunoassay for detection of Toxoplasma-specific IgM antibodies. Diagn Microbiol Infect Dis. 1992;15:587-593.
16. Safford JW, Abbott GG, Craine MC, et al. Automated microparticle enzyme immunoassays for IgG and IgM antibodies to Toxoplasma gondii. J Clin Pathol. 1991;44:238-242.
17. Enders G, Knotek F. Comparison of the performance and reproducibility of various serological methods and diagnostic kits for the detection of rubella antibodies. J Virol Methods. 1985;11:1-14.
18. Diepersloot RJ, Dunnewold-Hoekstra H, Kruit-Den Hollander J, et al. Antenatal screening for hepatitis B and antibodies to Toxoplasma gondii and rubella virus: evaluation of two commercial immunoassay systems. Clin Diagn Lab Immunol. 2001;8:785-787.
19. Vlaspolder F, Singer P, Smit A, et al. Comparison of Immulite with Vidas for detection of infection in a low-prevalence population of pregnant women in the Netherlands. Clin Diagn Lab Immunol. 2001;8:552-555.
20. Decoster A, Lambert N, Germaneau C, et al. Toxoplasmosis serodiagnosis: comparison of Access Toxo IgM II assay compared to Axsym Toxo IgM and Vidas Toxo IgM assays [in French]. Ann Biol Clin (Paris). 2000;58:721-727.
21. Hofgartner WT, Swanzy SR, Bacina RM, et al. Detection of immunoglobulin G (IgG) and IgM antibodies to Toxoplasma gondii: evaluation of four commercial immunoassay systems. J Clin Microbiol. 1997;35:3313-3315.
22. Luyasu V, Robert AR, Schaefer L, et al, for the Multicenter Study Group. Multicenter evaluation of a new commercial assay for detection of immunoglobulin M antibodies to Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 1995;14:787-793.
23. Partanen P, Turunen HJ, Paasivuo RT et al. Immunoblot analysis of Toxoplasma gondii antigens by human immunoglobulins G, M, and A antibodies at different stages of infection. J Clin Microbiol. 1984;20:133-135.
24. Liesenfeld O, Press C, Montoya JG, et al. False-positive results in immunoglobulin M (IgM) Toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol. 1997;35:174-178.
25. Hudson P, Morgan-Capner P. Evaluation of 15 commercial enzyme immunoassays for the detection of rubella-specific IgM. Clin Diagn Virol. 1996;5:21-26.